Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repligen and Bristol-Myers Squibb settle Orencia lawsuit
The settlement provides for Bristol-Myers Squibb to make an initial payment of $5 million and to pay royalties on the US net sales of Orencia for any clinical
The settlement provides for Bristol-Myers Squibb to make an initial payment of $5 million and to pay royalties on the US net sales of Orencia for any clinical
The data show substantially greater exposure to tizanidine from the oral spray (OS) formulations and earlier detectable plasma drug levels for OS doses versus the tablet (approximately 10
Fieldtests has also agreed to distribute company’s QuikSense Drugs-of-Abuse products through its distribution channels, and intends to add other QuantRx products, such as RapidSense and OralSense, as they
Presently, the company holds over 220 issued patents and pending patent applications world-wide, which cover novel agonists and antagonists of TLRs 7, 8 and 9. Steven Ritter, vice
The compound was designed to selectively inhibit the production of PCSK9 and could offer a new and complementary mechanism to current lipid-lowering therapies for the prevention and treatment
The Phase I clinical trial was a randomized, open-label, single dose, single center, two-period crossover trial designed to examine the safety, tolerability, pharmacokinetic and pharmacodynamic profile of the
AllerNase (triamcinolone acetonide) nasal spray, an aqueous based intranasal steroid is indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis
The company intends to spin off LifeHealthCare (LHC) by authorizing the issuance of one share of common stock of LHC for every share of common stock each stockholder
The Phase Ib, open-label single-arm study will enroll up to approximately 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at multiple cancer centers in the
The company also announced that it has received corresponding patents from the South African and the New Zealand Patent Offices. In addition to these newly issued patents, the